CBO and the staff of the Joint Committee on Taxation estimate that enacting several portions of the bill would have no effect on direct spending or revenues: section 101, Price Transparency Requirements; section 102, Strengthening Health Insurer Transparency Requirements; section 104, Mandatory Reporting With Respect to Certain Health-Related Ownership Information; section 105, Increasing Price Transparency of Clinical Diagnostic Laboratory Tests Under the Medicare Program; section 106, Promoting Transparency of Common Ownership Interests Under Parts C and D of the Medicare Program; and section 305, PBM Reporting and Increased Flexibility.
